Figure 8.

EZM2302 strengthens the efficacy of immunotherapy by promoting ferroptosis. a) Treatment protocol for MC38 xenografts in C57 mice following treatment with mouse anti‐PD1 antibody and EZM2302. b) MC38 cells were subcutaneously injected into the mice, and tumors were treated with mouse anti‐PD1 antibody and EZM2302. After tumors grew to 100 mm³, tumor volumes (n = 5) were calculated every 3 days, and the growth curve was drawn. c,d) Images of tumor size in different groups are shown, and the tumor weights (n = 5) of the subcutaneous xenografts were measured. e) Representative dot plot of mouse CD8⁺ T cells examined for the expression of interferon γ (IFN‐γ) (left) and granzyme B (GzmB) (right) after the indicated treatments. The proportions of cells with IFN‐γ or GzmB expression are shown on the left (n = 5 independent experiments). f,g) Representative contour plots of human peripheral CD8⁺ T cells examined for the expression of IFN‐γ (middle left) and granzyme B (GzmB) (bottom left) after the indicated treatments. h,i) Malondialdehyde (MDA) levels and relative lipid ROS in tumor cells isolated from (d) were assayed (n = 5 independent experiments). The data shown represent the mean ± SD. Comparisons were made by using one‐way ANOVA with Tukey's test; ^** p < 0.01, ^*** p < 0.001.